Abstract: Disclosed is a test device and method for remote control parking, falling within the technical field of testing. The method provided by the present disclosure includes the following steps: responding to a remote control parking instruction sent by a portable terminal, and acquiring position and pose data of a vehicle in real-time; injecting function loss conditions; determining a stopping position of the vehicle according to the position and pose data if an alarm signal or a parking success signal sent by an in-vehicle infotainment system is received; and determining a test result of remote control parking according to the stopping position of the vehicle and the function loss conditions. The present disclosure is used to test the response of a vehicle parking under the function loss condition.

Abstract: Disclosed are an OTA test method for a vehicle antenna system, a device and a storage medium. According to the method, the radio frequency performance of a physical layer of a whole vehicle antenna system can be tested, and the problem in the prior art that the test result of parts cannot accurately reflect the performance of the whole vehicle antenna system can be solved.

Abstract: A testing method for a blind spot detection system for an automobile includes: applying an electromagnetic interference signal to the tested automobile through an electromagnetic interference signal application device, meanwhile, simulating a static obstacle or a moving obstacle within a detection range through a testing device, and if the blind spot detection system for the tested automobile is activated, determining that the testing is passed. Repeatable and reproducible testing for the electromagnetic safety of the blind spot detection system may be realized.

Abstract: A polypeptide targeting integrin ?6 and the use thereof. The polypeptide has a sequence motif of RWYD, and is stronger in affinity, wherein the equilibrium dissociation constant KD reaches the level of nM, and the affinity is greatly improved. The polypeptide has a strong affinity to integrin ?6, a strong specificity and no biological toxicity, is relatively stable in vivo and reasonable in distribution, and can be used as a targeting carrier. In addition, the polypeptide targeting integrin ?6 can be used as a molecular probe in the molecular imaging of various tumors with highly-expressed integrin ?6. Further provided is a dimer of the polypeptide, which has a more significant targeting effect and no biological toxicity. The polypeptide targeting integrin ?6 can be used in the molecular imaging of various tumors with highly-expressed integrin ?6, and has an important application value in the molecular imaging of tumors.

Abstract: The present invention is related to a self-assembled nanoparticle containing a gB protein of an EB virus and a preparation method and use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide; the first polypeptide comprises the gB protein and a first vector subunit, the second polypeptide comprises a second vector subunit; the first vector subunit is I53-50A1, and the second vector subunit is I53-50B.4PT1. In the self-assembled nanoparticle, the gB protein of the EB virus is displayed on the surface of the nanoparticle for the first time. The particle size of the self-assembled nanoparticle is larger than that of the antigen gB, and the chemical stability of the self-assembled nanoparticle is higher than that of the antigen gB, and the binding capacity with the neutralizing antibody of the self-assembled nanoparticle are higher than that of the antigen gB.

Abstract: Disclosed is a self-assembled nanoparticle containing a gHgL protein of an EB virus, a preparation method and use thereof. The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a gHgL protein and a first vector subunit, and the second polypeptide comprises a second vector subunit; the first vector subunit is 153-50A1, and the second vector subunit is 153-50B.4PT1; and the gHgL protein is linked to the first vector subunit through a linker. The gHgL protein of the EB virus is displayed on a surface of the self-assembled nanoparticle for the first time. The self-assembled nanoparticle has a larger particle size than the antigen (gHgL), a better antigen residence volume, and a thermal stability comparable to the antigen (gHgL). Moreover, since a larger number of gHgLs are displayed, the self-assembled nanoparticle can strongly stimulate more B cells and induce higher antibody titer.

Abstract: Disclosed are a fusion protein, and a preparation method and use thereof, which belong to the field of biomedicine technologies. The fusion protein comprises a polypeptide specifically bound to a KRas protein, a specific tumor-cell-penetrating peptide and a lysosome recognition peptide. The fusion protein with tumor targeting, penetrability and specific protein degradation is designed and constructed direct to an undruggable protein for the first time, thus providing a new idea for development of an anti-cancer targeted drug. Different from the prior art in which one molecule can only target one target protein, the fusion protein can simultaneously induce degradation of wild-type and mutant-type KRas proteins. Meanwhile, the fusion protein can improve the sensitivity of the KRas mutant-type tumor to the tumor-targeted drug by inducing degradation of KRas, thus expanding an application range of existing anti-cancer targeted drugs and having important significance in tumor clinic treatment.

Abstract: Disclosed are a self-assembled nanoparticle containing a gB protein of an EB virus and a preparation method and use thereof The self-assembled nanoparticle comprises a first polypeptide and a second polypeptide; the first polypeptide comprises the gB protein and a first vector subunit, the second polypeptide comprises a second vector subunit; the first vector subunit is I53-50A1, and the second vector subunit is I53-50B.4PT1. In the self-assembled nanoparticle provided herein, the gB protein of the EB virus is displayed on the surface of the nanoparticle for the first time. The particle size of the self-assembled nanoparticle is larger than that of the antigen gB, and the chemical stability of the self-assembled nanoparticle is higher than that of the antigen gB, and the binding capacity with the neutralizing antibody of the self-assembled nanoparticle are higher than that of the antigen gB.

Abstract: The invention discloses an ATP1A1-targeting polypeptide and the use thereof. The motif of the ATP1A1-targeting polypeptide is represented by the general formula of SISSLTH, and the C- and/or N-terminal(s) of the motif is/are optionally linked with 1-3 amino acids. It is demonstrated by experiments that the ATP1A1-targeting polypeptide can target ATP1A1 well, and has great application value in the molecular diagnosis and targeted therapy of tumors.

Abstract: A tumor-targeting peptide is disclosed. This tumor-targeting peptide comprises a typical motif with the general formula of: XX(Y/F) (D/E) (D/E) XX. The motif is selectively connected with 1-3 amino acids at the C-terminal and/or N-erminal. X represents any one of the twenty natural amino acids or the D type amino acids. The present invention also discloses that the peptide can not only target tumor vessels and tumor cells but also penetrate them and thus can be applied in tumor diagnosis and therapy.

Abstract: This invention provides a tumor-targeting peptide. This tumor-targeting peptide comprises a typical motif with the general formula of: XX(Y/F) (D/E) (D/E) XX. The motif is selectively connected with 1-3 amino acids at the C-terminal and/or N-terminal. X represents any one of the twenty natural amino acids or the D type amino acids. The present invention also discloses that the peptide can not only target tumor vessels and tumor cells but also penetrate them and thus can be applied in tumor diagnosis and therapy.